Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)

Dr Samuel W Golden, Pittsburgh

West Paces Clinical Research Incoporated, Atlanta

Stratogen of South Florida, Miami Beach

Saint Joseph's Hosp / Infectious Disease Rsch Institute, Tampa

Dallas Veterans Administration Med Ctr, Dallas

Dr Daniel Barbero, Fort Worth

Park Plaza Hosp, Houston

Shared Med Research Foundation, Tarzana

Dr Marcus Conant, San Francisco